HC Wainwright & Co. Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target

MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.

MPLT

0.00

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MapLight Therapeutics (NASDAQ: MPLT) with a Buy and maintains $45 price target.